Morgan Stanley Charles River Laboratories International, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Morgan Stanley holds 468,198 shares of CRL stock, worth $91.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

468,198

Previous 481,774 2.82%

Holding current value

$91.7 Million

Previous $99.5 Million 7.33%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$187.96 - $245.29 $2.55 Million - $3.33 Million	-13,576 Reduced 2.82%	468,198 $92.2 Million
Q2 2024 Oct 17, 2024	BUY	$206.39 - $268.73 $9.64 Million - $12.6 Million	46,715 Added 10.74%	481,774 $99.5 Million
Q2 2024 Aug 14, 2024	BUY	$206.39 - $268.73 $9.64 Million - $12.6 Million	46,715 Added 10.74%	481,774 $99.5 Million
Q1 2024 Oct 17, 2024	SELL	$203.52 - $273.43 $9.51 Million - $12.8 Million	-46,715 Reduced 9.7%	435,059 $118 Million
Q1 2024 Aug 16, 2024	SELL	$203.52 - $273.43 $7.54 Million - $10.1 Million	-37,051 Reduced 7.85%	435,059 $118 Million
Q1 2024 May 15, 2024	SELL	$203.52 - $273.43 $7.54 Million - $10.1 Million	-37,051 Reduced 7.85%	435,059 $118 Million
Q4 2023 Aug 16, 2024	SELL	$164.52 - $238.84 $1.59 Million - $2.31 Million	-9,664 Reduced 2.01%	472,110 $112 Million
Q4 2023 Feb 13, 2024	SELL	$164.52 - $238.84 $8.75 Million - $12.7 Million	-53,183 Reduced 10.12%	472,110 $112 Million
Q3 2023 Nov 15, 2023	BUY	$194.44 - $217.61 $2.4 Million - $2.69 Million	12,342 Added 2.41%	525,293 $103 Million
Q2 2023 Aug 14, 2023	BUY	$183.71 - $210.25 $10.8 Million - $12.3 Million	58,539 Added 12.88%	512,951 $108 Million
Q1 2023 May 15, 2023	SELL	$191.89 - $259.92 $3.84 Million - $5.2 Million	-20,019 Reduced 4.22%	454,412 $91.7 Million
Q4 2022 Feb 14, 2023	BUY	$197.11 - $250.07 $38.1 Million - $48.3 Million	193,250 Added 68.73%	474,431 $103 Million
Q3 2022 Nov 14, 2022	SELL	$182.44 - $250.54 $9.23 Million - $12.7 Million	-50,606 Reduced 15.25%	281,181 $55.3 Million
Q2 2022 Oct 27, 2022	BUY	$204.13 - $302.4 $28.3 Million - $42 Million	138,733 Added 71.86%	331,787 $71 Million
Q2 2022 Aug 15, 2022	BUY	$204.13 - $302.4 $28.3 Million - $42 Million	138,733 Added 71.86%	331,787 $71 Million
Q1 2022 Oct 27, 2022	SELL	$255.51 - $362.11 $35.4 Million - $50.2 Million	-138,733 Reduced 41.81%	193,054 $54.8 Million
Q1 2022 May 13, 2022	SELL	$255.51 - $362.11 $1.53 Million - $2.17 Million	-5,994 Reduced 3.01%	193,054 $54.8 Million
Q4 2021 Feb 14, 2022	BUY	$351.38 - $448.68 $4.06 Million - $5.18 Million	11,556 Added 6.16%	199,048 $75 Million
Q3 2021 Nov 15, 2021	BUY	$372.64 - $458.3 $69.9 Million - $85.9 Million	187,492 New	187,492 $77.4 Million

Others Institutions Holding CRL

# of Institutions

696

Shares Held

52.3M

Call Options Held

259K

Put Options Held

463K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $9.96B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account